RELATED CONTENT
NEWS
- Tysabri risk analysis offers personalised medicine opportunity
- Biogen claims oral MS drug BG-12 could outperform Gilenya
- Biogen/Elan hope updated Tysabri label will lend confidence to patients/prescribers
- Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
ANALYSIS
Other Informa Analysis
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

